CBD for Pain: Do CBD Oil, Gummies and Creams Work? (November 2026)

Reviewed by: Bryan Doner, MD, & Cannabidiol Life’s Medical Review Team

INTRODUCTION:

Several small randomized trials found less pain with CBD, while most larger trials found no difference from placebo. See every trial in our review, the forms and amounts tested, and the safety facts.
Folded sage yoga mat and rolled cotton towel on a sunlit light oak floor in morning light

Table of Contents

Data as of October 23, 2026; trial data updated November 13, 2026

Research on CBD (cannabidiol) for pain is mixed and low-certainty. Of 44 randomized trials of CBD alone or CBD-dominant products in our review, 7 found a benefit, 5 had mixed or early results, 29 found no advantage over placebo (a dummy product) and 3 could not be judged against placebo. A 2024 Journal of Pain review found no benefit in nearly all its trials. Products that also contain THC, the intoxicating compound in cannabis, showed small benefits in some trials, with more side effects.

The FDA has not approved CBD for pain. The FDA has approved only one drug that contains CBD: Epidiolex, a prescription medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in people 1 year of age and older.

CBD (cannabidiol) is a non-intoxicating cannabinoid from the Cannabis sativa plant, including hemp.

Key takeaways

  • Several small randomized trials found less pain with CBD in severe toothache (61 adults), nerve pain after spinal cord injury (40 people) and, with CBD on the skin, thumb arthritis, jaw muscle pain and nerve damage (18 to 60 people). Most other trials, including the 8 largest (100 to 200 people), found no advantage over placebo, as did nearly all in a 2024 Journal of Pain review. [1]
  • Earlier trials found a benefit more often: 3 of the 5 published before 2021 (20 to 60 people each) found less pain, vs 4 of the 39 from 2021 on (5 more mixed or early), as trials grew larger and mostly gave CBD by mouth. In the largest, 200 adults with fibromyalgia, pain fell more on placebo than on CBD over 24 weeks. [4]
  • A 2026 US government-funded (AHRQ) review found that products with THC gave small pain benefits with more side effects, and that low-THC, CBD-dominant products may not improve chronic pain. [2]
  • Research is continuing: as of October 23, 2026, ClinicalTrials.gov lists 123 CBD-for-pain studies, 38 of them open and 22 first registered in 2025-2026; 14 of the 46 completed ones have posted results (compiled by Cannabidiol Life). Evidence Tracker
  • A 2023 meta-analysis found liver-enzyme rises in about 7% of trial participants taking CBD; high doses (1,000 mg a day or 20 mg/kg a day and above) and use with seizure medicines raised the risk, and no cases were reported in adults taking under 300 mg a day. [5]

Does CBD help with pain? What the research shows

Evidence for CBD alone is mixed and low-certainty. Small trials found lower pain with single doses in severe toothache, high daily doses in nerve pain after spinal cord injury, and CBD applied to the skin in thumb arthritis, jaw muscle pain and nerve damage in the legs (see the study table and topical CBD below). Most larger trials found no difference from placebo. In a 2024 Journal of Pain review, 15 of 16 randomized CBD trials found no pain benefit over placebo. A 2026 Cochrane review of 5 trials (208 people) found no clear benefit from CBD-dominant medicines for nerve pain (very low certainty).

The research has changed over time. Of the 5 CBD trials in our review published before 2021, 3 found lower pain; all 5 were small (20 to 60 people), and 2 of the 3 favorable ones applied CBD to the skin. Of the 39 published from 2021 on, which include all 8 trials with 100 or more people and mostly gave CBD by mouth, 4 found lower pain, 5 had mixed or early results, 28 found no advantage and 2 could not be judged (1 descriptive, 1 compared only with codeine plus acetaminophen). Among the newest, a 2026 pilot of 36 adults having both knees replaced had mixed results (planned test: no significant difference in opioid use; a post hoc test favored 400 mg doses), and two trials that gave healthy adults a single dose before a run found no change in pain, a secondary rating in both.

The US Agency for Healthcare Research and Quality (AHRQ) funded a 2026 systematic review that pooled 25 placebo-controlled trials with 2,303 people. It found that low-THC, CBD-dominant products may not improve chronic pain. The National Academies’ 2017 “substantial evidence” finding for chronic pain was about cannabis, mostly with THC, not CBD alone.

A 2024 review of 15 mixed studies of CBD with or without THC reports pain drops of 42% to 66%, while 3 of its studies found no significant improvement. The review did not pool results, so the range is not an effect over placebo.

CBD alone vs CBD with THC: why the product matters

Several small trials of CBD alone found less pain, while most found no difference from placebo; products with THC showed small effects with more side effects. In the AHRQ review, balanced THC:CBD mouth sprays such as nabiximols (Sativex, 1:1) probably cut pain by 0.54 points on a 0-10 scale (moderate certainty). THC-only products taken by mouth cut it by 0.78 points (low certainty). Both brought more dizziness, sedation and nausea.

Further reviews, meta-analyses, guidelines and one expert consensus paper reported a benefit or a favorable signal for medical cannabis or cannabis-based medicines in pain. The table lists 8 of them as of November 13, 2026; this is a selection, not a full list. Their main favorable findings are for medicines that contain THC or for all products pooled, not for CBD alone. Reviews that found no benefit or no clear benefit for CBD itself are cited above, such as the 2024 Journal of Pain review and the 2026 Cochrane review. So is the 2026 AHRQ review of chronic-pain trials, which found that low-THC, CBD-dominant products may not improve chronic pain.

Review What it covered Products What it reported Its own limit
Jeddi 2024 Network meta-analysis of 90 randomized trials (22,028 people with chronic non-cancer pain, followed for 28 to 180 days): 66 trials of opioids vs placebo, 23 of cannabis for medical use vs placebo (3,435 patients) and 1 of the cannabinoid nabilone vs the opioid dihydrocodeine All cannabis-for-medical-use products pooled, with no inhaled cannabis: 18 of the 23 placebo-controlled cannabis trials used THC with CBD or THC alone, and 2 used CBD. No separate CBD result Low to moderate certainty evidence that cannabis for medical use gave small improvements in pain, physical functioning and sleep quality vs placebo, similar to those of opioids; moderate-certainty evidence that fewer people stopped cannabis than opioids because of side effects Low-certainty evidence for its finding of little to no difference in pain relief between cannabis and opioids, with 1 trial comparing the two directly; 75 of the 90 trials were at high risk of bias in at least one area
Bell 2024 Clinical practice guideline built on a systematic review of 70 articles (19 systematic reviews and 51 original studies). For pain it reviewed 47 studies: 22 randomized trials, 11 before-and-after or uncontrolled studies, 11 cross-sectional or observational cohort studies and 3 case series Cannabinoid-based medicines of all kinds, as a group. The guideline says the strongest evidence for reducing chronic pain symptoms is for THC formulations, not CBD. It notes a single study, published as an abstract, that suggested a benefit from CBD on the skin (the amount that study used was 125 mg twice a day) for knee osteoarthritis pain, and says topical products need more research Research typically shows moderate benefit of cannabinoid-based medicines in chronic pain; 38 of the 47 pain studies reported at least moderate benefits. Strong recommendation, on moderate-quality evidence, to use them to improve chronic pain outcomes 7 of the 47 pain studies were inconclusive or found insufficient evidence and 2 had mixed results; unblinding in placebo-controlled trials is a possible source of bias; few studies compare these medicines with usual pain treatments. The guideline was funded by the Canadian Institutes of Health Research, the Arthritis Society of Canada and the cannabis company Canopy Growth Corporation, which the authors say played no role in developing it; several authors, the first author among them, report ties to cannabis companies
Solmi 2023 Umbrella review of 101 meta-analyses (51 of randomized trials and 50 of observational studies) on cannabis, cannabinoids and cannabis-based medicines across many health outcomes. Its chronic pain results come from meta-analyses of randomized trials Cannabis-based medicines or cannabinoids, as a group. No CBD result for pain; its main CBD findings are for epilepsy High-certainty evidence that more people with chronic pain reached a 30% drop in pain on cannabis-based medicines or cannabinoids (a share of people, not an average 30% fall in pain), and seven further pain benefits rated moderate certainty. It concluded that cannabis-based medicines are effective in people with chronic pain “but not without adverse events” With the same high certainty, no effect on average pain relief; at moderate certainty, no effect on a 50% pain reduction or on patients’ overall impression of improvement. In chronic pain the medicines increased psychological distress and withdrawals because of side effects (moderate certainty); across mixed conditions they caused more nervous-system, psychological and vision side effects (high certainty)
Bilbao 2022 Meta-analysis of 152 randomized trials (12,123 participants) across many medical conditions, with each cannabinoid analyzed on its own. Chronic pain comparisons with placebo: dronabinol 15 trials (1,395 people), nabilone 9 trials (363), nabiximols 21 trials (3,238) and CBD 1 trial (129) Each cannabinoid on its own: dronabinol (a synthetic THC), nabiximols (THC with CBD), nabilone (a synthetic cannabinoid) and CBD. For CBD alone, the single chronic pain trial (20 mg or 30 mg a day for 12 weeks; the hand and psoriatic arthritis trial already on this page) showed no effect Moderate-grade evidence of a chronic pain benefit for dronabinol and for nabiximols, and low-grade evidence of one for nabilone The moderate-grade pain evidence is for medicines that contain THC; apart from the few results its summary names, these among them, its significant effects had low, very low or no grade of evidence; cannabinoids caused side effects
Busse 2021 Clinical practice guideline (a BMJ Rapid Recommendation) from an international panel of patients, clinicians and experts in research methods, built on four linked systematic reviews of benefits, harms and patient values and preferences. It covers people living with chronic cancer or non-cancer pain Non-inhaled medical cannabis or cannabinoids, as one group. Its summary makes no separate statement on CBD A weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids, in addition to standard care, when standard care is not enough Weak because benefits and harms are closely balanced; the improvements it weighs in pain, physical functioning and sleep quality are small to very small; the panel says further research may change the recommendation
Wang 2021 Meta-analysis of 32 randomized trials (5,174 adults): 28 trials in chronic non-cancer pain and 4 in cancer-related pain; 29 compared the product with placebo; follow-up of 1 to 5.5 months Non-inhaled medical cannabis or cannabinoids, pooled as one group: taken by mouth in 30 trials and put on the skin in 2. The summary gives no separate result for CBD or for products with THC Moderate-certainty evidence that these products probably lead to a small increase in the share of patients whose pain improves by at least 1 cm on a 10 cm scale (a modeled difference of 10% of patients), based on average pain 0.50 cm lower than with placebo The authors called the improvements in pain relief, physical functioning and sleep quality small to very small, and reported several short-lived side effects, among them dizziness, drowsiness and nausea. The paper reports no industry funding for the work; one author is chief medical officer of the cannabis company Canopy Growth Corporation, and two received honoraria from the cannabis companies Spectrum Therapeutics and Tilray
Bhaskar 2021 Expert consensus reached by a multistage modified Delphi process: 20 experts from 9 countries on how to dose and give medical cannabis for chronic pain. Expert opinion, not trial results; no trials were pooled Medical cannabis. Two of its three protocols start with a CBD-predominant product and may add THC; the third starts with a balanced THC:CBD product. These are protocols proposed by experts, not measured effects of any product Consensus that medical cannabis may be considered for patients with neuropathic (nerve), inflammatory, nociplastic and mixed pain Expert consensus, written because there are few randomized trials of medical cannabis. The work was funded by Spectrum Therapeutics, a Canopy Growth company, which influenced the choice of experts but, the authors say, not the discussions or votes; all authors received compensation from it
Fisher 2021 Systematic review of 36 randomized trials (7,217 participants) in people of any age with any type of pain: 8 studies of cannabinoids, 6 of cannabis and 22 of cannabis-based medicines, with treatment shorter and longer than 7 days analyzed separately Cannabinoids, cannabis and cannabis-based medicines. Its two favorable results are for cannabis and for nabiximols (THC with CBD), both of which contain THC; the summary gives no CBD-only result Evidence of benefit in two analyses: cannabis used for less than 7 days (2 trials, 231 patients) and nabiximols used for more than 7 days (6 trials, 1,484 patients) Both results rest on very low-quality evidence; no other beneficial effects were found in the primary analyses, and all studies had high or uncertain risk of bias. The authors concluded that the evidence “neither supports nor refutes claims of efficacy and safety”

Several of these overlap and are not independent bodies of evidence. Busse 2021 is the guideline built partly on Wang 2021, and Jeddi 2024 comes from the same research group. Solmi 2023 is an umbrella review whose chronic pain results come from earlier meta-analyses, Wang 2021 among them, and several of the others draw on many of the same trials.

User reports, surveys and placebo responses

People who use CBD for pain take real-world products at their own doses and for their own lengths of time. Some of those products contain THC (see the product tests below), and in a 2022 survey of people with fibromyalgia, the doses people reported were similar to some trials and far below others (see the dose section). A 2025 analysis of the same survey, limited to 1,382 women who also had chronic pelvic pain, found that 34.5% were current CBD users; 80.9% of those 477 users reported that their pain improved, and about half reported side effects, mostly minor. In a UK registry of 3,744 people prescribed medical cannabis for chronic pain (not a CBD-only study: by 24 months the median daily dose was 126.5 mg of THC and 20.5 mg of CBD; no comparison group), pain severity and pain interference scores improved from the start to 24 months, and more than half of patients reached a meaningful improvement on each pain measure at 24 months; 14.37% reported adverse events, mostly mild or moderate. Placebo responses in pain trials can also be large: in the fibromyalgia trial, pain fell 1.1 points on placebo and 0.4 on CBD. Surveys and personal reports can’t separate CBD’s effect from placebo responses or other treatments; randomized trials are designed to do that.

CBD trials for pain: the study table (November 2026)

The tally at the top of this page counts 44 randomized studies of CBD alone or CBD-dominant products for pain that we verified (compiled by Cannabidiol Life, as of November 13, 2026). The trials with no advantage over placebo include 2 where placebo did better. Three could not be judged against placebo: 1 descriptive, 1 with no separate CBD result, and 1 after eye surgery where pain on CBD did not differ from codeine plus acetaminophen, with no placebo group. All 44 are in the appendix.

The table shows the 8 largest trials by total enrollment (100 or more people each; none found a benefit, and in 2 of them about 30 people took CBD alone, with the rest in placebo or THC-containing groups), 5 smaller trials discussed below (3 found less pain) and 2 trials of products with THC.

Evidence grade is how much weight a study can carry: High = large, well-run randomized trial; Moderate = adequate randomized trial with limits; Low = small trial or one without a placebo group.

Study Pain type and people People CBD amount, form and length Result vs comparator Evidence grade
CBD alone or CBD-dominant: the 8 largest trials
Rasmussen 2026 Fibromyalgia 200 50 mg/day tablets, 24 weeks Pain fell more on placebo High
Hardy 2023 Advanced cancer 144 Oil, up to 600 mg/day, 28 days No difference, including pain Moderate
Vela 2022 Hand osteoarthritis or psoriatic arthritis 136 20-30 mg/day, 12 weeks No difference Moderate
Hansen 2023 Nerve pain with MS or spinal cord injury 134 (31 on CBD) Up to 45 mg/day, 6 weeks No difference Moderate
Zubcevic 2023 Nerve pain (nerve disease, shingles, injury) 118 (4 groups) Capsules, 5-50 mg/day, 8 weeks No benefit; CBD group about 1 point worse Moderate
Anelli 2026 Endometriosis pelvic pain 102 CBD-enriched oil, 10-150 mg/day, 10 weeks No difference; stopped early Moderate
Kubota 2026 Parkinson’s disease pain 101 CBD-dominant oil, about 44 mg/day, 9 weeks No difference Moderate
Bebee 2021 Sudden low back pain 100 Single 400 mg dose No difference at 2 hours Moderate
Smaller CBD trials discussed in this article
Pramhas 2023 Knee osteoarthritis, on paracetamol 86 600 mg/day, 8 weeks No difference; more liver-enzyme rises (15 vs 5 people) Moderate
Zhou 2026 After eye surgery 35 50 mg twice a day No difference from codeine plus acetaminophen; no placebo Low
Robertson 2026 Nerve pain after spinal cord injury 40 Up to 800 mg/day, 6 weeks Pain 0.54 points lower (0-10 scale) Low
Chrepa 2024 Severe toothache 61 Single 10 or 20 mg/kg dose Pain lower than placebo over 3 hours; more sedation Low
Heineman 2022 Thumb arthritis 18 6.2 mg/mL cream, twice a day, 2 weeks Lower pain than the control cream Low
For comparison: products with THC
Langford 2013 MS nerve pain 339 Nabiximols spray (THC:CBD about 1:1), 14 weeks Main goal not met High
Karst 2025 Chronic low back pain 820 THC extract with almost no CBD, 12 weeks Pain 0.6 points lower; more side effects High

Rows verified at PubMed as of October 23, 2026; the tally above the table is as of November 13, 2026.

CBD for pain by the numbers (October 2026)

Compiled by Cannabidiol Life from ClinicalTrials.gov, PubMed and Ahrefs.

Metric Figure Source
Registered studies 123 of CBD alone or CBD-dominant products; 63 of CBD with THC (22 nabiximols) ClinicalTrials.gov query
Completed with posted results CBD: 14 of 46 (30.4%); CBD+THC: 24 of 35 (68.6%) Same
Open or new 38 of 123 open; 22 first registered in 2025-2026 (11 each year) Same
Study size Median 40 people; 6,886 enrolled (67 studies); 56 more plan 5,364 Same
Phase and design 7 Phase 3, 5 Phase 4, 13 Phase 2/3, 40 Phase 2; 88 randomized with placebo or sham Same
PubMed papers 1,538 on cannabidiol and pain; 195 in 2025 vs 14 in 2015; 190 in 2026 so far PubMed query
Trials and reviews 71 tagged as randomized controlled trials (4.6%; not all test CBD for pain); 59 systematic reviews; 14 meta-analyses PubMed RCT query
US monthly searches, “cbd for pain” Peak 19,217 (June 2019); 12-month average 4,571 (76.2% below peak; -0.2% in the past year) Ahrefs Keywords Explorer, US

As of October 23, 2026.

Which kinds of pain are being studied

Pain type CBD studies CBD+THC studies
Nerve (neuropathic) pain 18 15
Arthritis and joint pain 20 2
Muscle, jaw and other musculoskeletal pain 16 0
Surgery and injury 14 1
Back, neck and spine 5 6
Cancer 4 15

The number of registered studies shows research interest, not study results.

Method: we read every ClinicalTrials.gov record by hand; “CBD” means no deliberate THC dose, or THC below one-tenth of the CBD dose. A registered study is not a result, and posted results miss journal-only results.

Cite this data: Cannabidiol Life, “CBD for Pain by the numbers (October 2026),” cbdoilsandedibles.com, https://cbdoilsandedibles.com/health/cbd-for-pain/, data as of 2026-10-23.

CBD for chronic, nerve, cancer and other types of pain

Pain type What the trials in this article found Read more
Chronic pain and fibromyalgia Fibromyalgia: in the largest trial, pain fell more on placebo [4]; for other long-lasting pain, see the nerve and joint rows More
Nerve pain, MS and spinal cord injury Oral: 1 high-dose trial modestly lower pain, 2 lower-dose trials no advantage over placebo [12][11][18]; on the skin: 1 trial lower pain, 1 no difference (see topical CBD) More
Cancer No difference [9] More
Back pain No difference [15] More
After surgery or dental work Toothache: lower pain [19]; eye surgery: no difference from codeine plus acetaminophen [17]; replacement of both knees: mixed results (planned test: no significant difference in opioid use; a post hoc test favored 400 mg) [50] More
Muscle soreness after exercise 1 small trial found early signs of less pain; other small studies found no change [23][24]; 2 trials of a single dose before a run: no change in pain [51][52] More
Joint pain Cream trial (18 people): lower pain; 2 trials by mouth (86 and 136 people): no difference [16][10][20] CBD for arthritis
Migraine In a 2026 crossover trial of 92 adults, flower with THC plus CBD left more attacks pain-free (34.5% vs 15.5%); vaporized CBD-dominant cannabis flower was no better than placebo at 2 hours [25] Appendix
Pelvic and other pain Endometriosis and Parkinson’s pain: no difference [13][14] Table

CBD for chronic pain and fibromyalgia

A 2022 review counted pain as chronic when it lasted more than 3 months. CBD trials in long-lasting pain that found less pain include nerve pain after spinal cord injury and a cream for thumb arthritis (see below). In fibromyalgia, a 2026 pilot trial of 24 people found at least 30% less pain in 70% of people on a 1:1 THC:CBD oil vs 20-40% on placebo; no trial of CBD alone or CBD-dominant products in our review found a benefit. A 2026 meta-analysis of 12 fibromyalgia studies (2 randomized trials and 10 observational studies; 1,248 patients) found that pain intensity fell after people took cannabinoids. This held in follow-ups shorter than 3 months and in those of 3 months or longer. It pooled cannabinoids as a group, and its summary names no products and gives no separate CBD result. It compared pain before and after treatment, not with placebo, and its authors rated the evidence low and said to interpret it with caution. In 200 adults with fibromyalgia, pain fell more on placebo over 24 weeks, and in a 2019 trial of 20 people, inhaled CBD-dominant cannabis was no better than placebo.

Nerve (neuropathic) pain, including MS and spinal cord injury

In a 2026 crossover trial of 40 people with nerve pain after spinal cord injury (38 analyzed), pain was 0.54 points lower (0-10 scale) while taking CBD by mouth at up to 800 mg a day for 6 weeks than while taking placebo, a difference the authors called modest. Two trials of lower daily doses found no advantage over placebo. In a 4-group nerve-pain trial of 118 adults (about 30 per group) taking 5-50 mg a day, pain was not lower on CBD than on placebo; at 8 weeks the CBD group scored about 1 point worse.

In people with multiple sclerosis (MS) or spinal cord injury taking up to 45 mg a day, nerve pain scores on CBD did not differ from placebo. The 2026 crossover trial gave far higher doses than these two. Of 2 trials that applied CBD to the skin for nerve damage, 1 found lower pain and 1 found no difference (see topical CBD). A 2025 systematic review of 22 randomized trials of cannabis-based medicines for nerve pain (THC, CBD, the two together and others; not CBD alone) counted 15 that reported significant drops in pain and 7 that found no significant pain relief compared with placebo. Its authors listed small trials, short durations, high placebo response and unblinding as limits, and its summary does not split the count by product.

In a 2026 systematic review of 4 randomized trials in adults with painful nerve damage from diabetes, 3 trials reported significantly less nerve pain with cannabinoid-based products than with placebo and 1 did not. The one product its summary names is THC, vaporized or under the tongue: in 2 trials, THC doses of about 16-18 mg a day were linked to clinically meaningful pain relief, a range the authors called preliminary, not a recommendation. Its summary gives no CBD result, and its authors said the few small, varied trials and their risk of bias “preclude firm conclusions”. The European Pain Federation’s 2018 position paper, an expert panel’s reading of the research and its own clinical experience, said the evidence is such that cannabis-based medicines may be reasonably considered for chronic nerve pain. Its summary treats these medicines as a group and makes no separate statement on CBD (the 2026 Cochrane review near the top of this page covers CBD-dominant medicines). It says they should be considered only by experienced clinicians, as part of multidisciplinary care and preferably as an add-on when first- and second-line treatments have not worked well enough or were not tolerated.

Cancer pain

In the largest CBD-only trial in advanced cancer (144 adults), symptoms including pain improved about equally on CBD and placebo. In a 2026 survey of 1,258 cancer survivors, 18% had used CBD after diagnosis, 55% of them for pain. Most who used it for a symptom reported improvement (60% for nerve symptoms to 85% for energy or fatigue; the abstract gives no figure for pain), and 47% stopped early, most often because it did not help.

Pain after surgery, injury or dental work

In a 2024 trial of 61 adults with severe toothache, single doses of CBD lowered pain more than placebo over 3 hours, with more sedation and diarrhea. A trial after shoulder surgery found lower pain on day 1 only. In a 2026 pilot trial of 36 adults having both knees replaced, the planned test found no significant difference from placebo in opioid use over 72 hours; a post hoc test favored 400 mg doses, which also gave lower pain scores, while 800 mg doses gave more side effects (details under opioid use below). Two other trials after knee replacement, and trials after a kidney-stone procedure and root canal treatment, found no difference (appendix). Eye-surgery results are under Tylenol.

Does CBD help with muscle soreness after exercise?

One small trial in healthy volunteers found early signs of less pain, and other small studies found no change in soreness. In a 2021 trial of 13 men, CBD oil after hard exercise did not change muscle soreness. A 2026 feasibility trial of 29 adults reported less peak pain 48 hours after an induced muscle injury; its authors called these early estimates. In two placebo-controlled trials of a single CBD dose before a run, a 2024 trial of 52 healthy adults (51 analyzed; 150 mg) and a 2025 trial of 25 trained runners (50 or 300 mg), CBD did not change pain ratings; pain was a secondary rating in both.

Joint and arthritis pain

A cream trial in thumb arthritis found lower pain with CBD than with a control cream. Two trials of CBD by mouth, in 86 adults with knee osteoarthritis (8 weeks) and 136 with hand or psoriatic arthritis (12 weeks), found no difference from placebo. The cream trial had 18 people and lasted 2 weeks. More in CBD for arthritis.

Is CBD good for back pain? Back pain and sciatica studies

Research on CBD for back pain is limited. In a 2021 trial of 100 adults with sudden low back pain in an emergency department, pain 2 hours after one dose of CBD did not differ from placebo. The positive 820-person chronic low back pain trial tested a THC extract with almost no CBD.

A 2026 systematic review of 5 randomized trials (1,072 adults with low back pain, migraine or medication-overuse headache) rated as moderate-certainty the evidence for two products that contain THC. These were the full-spectrum cannabis extract VER-01 for chronic low back pain (the THC extract with almost no CBD from the 820-person trial above) and vaporized THC plus CBD for migraine at 2 hours. For CBD, a single 400 mg dose by mouth was not superior to placebo for sudden low back pain (evidence the review called very uncertain), and a CBD-dominant vaporized product showed no clear benefit for migraine. The review did not pool results and found no class-wide effect of cannabinoid-based treatments. Its main trials match ones already on this page; its other trials, of nabilone (a synthetic cannabinoid), showed favorable but very uncertain signals in medication-overuse headache and chronic musculoskeletal pain. A 2023 systematic review of 12 studies of medical cannabis for low back pain had 1 randomized trial, 6 observational studies and 5 case studies, testing cannabis products of many kinds, not CBD alone. It found that every study except the randomized trial pointed to less low back pain or less opioid use over time after medical cannabis use. Three of the case studies, in 4 people, used CBD alone. The randomized trial, the single 400 mg CBD dose trial above, found no significant difference from placebo. The authors found minimal high-quality evidence to support medical cannabis as a first-line treatment for low back pain.

We found no CBD-only sciatica trial.

How might CBD affect pain? What lab and animal studies show

The endocannabinoid system is the body’s network of cannabinoid receptors and the molecules that act on them. In animal and lab studies, CBD acted on many targets in pain pathways, a 2020 review reported. A 2021 meta-analysis of 374 animal studies, all in rodent models of lasting pain, found that CBD significantly reduced pain-related behaviors in models of nerve pain, with mixed results in models of inflammatory pain. Its authors wrote that the animal evidence supports the hypothesis of cannabinoid-induced pain relief. This is animal research: its authors said low reporting of steps to reduce bias left the risk of bias unclear, and 86% of the experiments used male animals. Almost all of that evidence came from animals and cells, so it shows how CBD might act rather than whether it eases pain in people; human trials test that.

For pain with swelling, see CBD for inflammation.

CBD oil, capsules, gummies or topicals: which forms have pain studies tested?

CBD taken by mouth lowered pain in some trials, such as single doses for severe toothache and high daily doses for nerve pain after spinal cord injury, while most oral trials found no difference from placebo. Several small skin-applied trials found lower pain, and we found no trial of gummies or smoked hemp flower.

Form How it is taken Absorption Pain trials in this article
Oil or tincture Under the tongue or swallowed Peak within 0-4 hours; higher with food or oily formulas [28] Cancer, Parkinson’s: no difference [9][14]
Capsule, tablet or softgel Swallowed As for other oral forms Nerve pain, fibromyalgia: no advantage over placebo; in fibromyalgia, pain fell more on placebo [12][4]
Gummy or edible Chewed and swallowed No gummy data in our sources No randomized trial found; 1 observational study of cannabis edibles for chronic low back pain (243 people; see gummies below) [55]
Cream, balm, gel or patch On the skin Not measured here Lower pain in small trials of thumb arthritis, nerve damage and jaw muscle pain [20][29][30]; no difference or mixed results in the others (appendix)
Vape or smoked flower Inhaled Fastest to peak in the blood [28] Vaporized CBD-dominant flower: no better than placebo in 2 trials (migraine, fibromyalgia) [25][31]; no trial of smoked hemp CBD flower found

Do CBD gummies work for pain?

We found no randomized trial of CBD gummies for pain. In a 2026 observational study of 243 adults with chronic low back pain who chose their own cannabis edibles for 14 days (97 CBD-dominant, 112 THC plus CBD, 34 THC-dominant), pain was lower on days people used their edible than on days they did not in the THC-dominant and THC-plus-CBD groups, but not in the CBD-dominant group, where the change was not significant. Higher THC doses, not higher CBD doses, were linked to lower pain, and 36.6% of the THC-plus-CBD group had at least 30% less pain by day 14; the study was not randomized and had no placebo. An earlier paper from the same study reported a trend, not statistically significant (p = .07), toward larger drops in pain over the 2 weeks with more frequent use of CBD-dominant edibles. In a 2025 test of 56 CBD gummy products, 70% were off their labeled CBD amount by more than 10%, and 39% contained THC.

Does topical CBD work for pain? Creams, balms and patches

Of 8 randomized trials in our review that applied CBD to the skin, 3 (18 to 60 people) found lower pain than a placebo or control cream: thumb arthritis, jaw muscle pain and nerve damage in the legs. Four (15 to 80 people) found no difference (knee replacement, chemotherapy nerve damage, exercise soreness) and 1 was mixed. A 2023 review rated earlier skin-applied trials, which mixed CBD with other ingredients, at high risk of bias. A 2022 study of 105 creams and patches found that 24% of those listing a CBD amount were accurately labeled, and 35% contained THC. No trial here compared creams with oral CBD.

How much CBD should I take for pain? What studies used

There is no official dose of CBD for pain, and research has not shown which amount helps a given person. In the trials in the study table, adults took CBD by mouth in daily amounts from 5 mg to 800 mg, and single doses went up to 20 mg/kg. The oral trials in the table that found lower pain used high amounts: up to 800 mg a day for nerve pain after spinal cord injury and single doses of 10 or 20 mg/kg for toothache. Trials of 5-50 mg a day found no advantage over placebo, as did 3 trials of 400-600 mg. In a 2022 survey, people with fibromyalgia who took CBD oils or edibles reported an average of 24-27 mg a day, and about a third did not know their dose. Some trials used similar amounts (20-50 mg a day); others used 400-800 mg. These are the amounts researchers used in studies. They are not dosing advice.

CBD vs Tylenol, ibuprofen and opioids: what has research compared?

Has CBD been compared with Tylenol (acetaminophen) for pain?

After eye surgery, pain in 35 adults did not differ between CBD and codeine plus acetaminophen; there was no placebo group. In 86 adults with knee osteoarthritis taking paracetamol (another name for acetaminophen), pain scores did not differ with added CBD or placebo.

Has CBD been compared with ibuprofen for pain?

No adequate trial has compared CBD with ibuprofen for pain. The one trial with an ibuprofen-and-acetaminophen group measured pain after tooth extraction in 8 people (2 per group) and reported its results descriptively. Advil is a brand of ibuprofen, so the same applies.

Can you take CBD with Tylenol or ibuprofen?

A 2021 review lists acetaminophen and opioid painkillers among the medicines CBD may interact with. In a trial of 86 adults taking acetaminophen 3 g a day, liver-enzyme rises were more common with added CBD than with placebo (see Drug interactions below). None of the trials in this article tested CBD together with ibuprofen. Ask your doctor or pharmacist before combining CBD with any pain medicine, including acetaminophen and ibuprofen.

What has research found about CBD and opioid use?

In a 2021 BMJ Open meta-analysis, observational studies suggested that adding medical cannabis lowered opioid use, while its 5 randomized trials, all in cancer pain, told people to keep their opioid dose. The meta-analysis rated all of this evidence very low certainty and found no reliable evidence that adding medical cannabis cuts opioid use. A 2024 systematic review of 15 studies of cannabinoids in people taking opioids for pain (7 randomized trials; the rest observational studies) found a significant drop in opioid use in three observational studies in chronic non-cancer pain. Two studied THC with CBD (the average amounts taken in those studies were 17 mg/15 mg a day) and one a CBD-rich extract (an average of 31.4 mg a day in that study). It reports no randomized trial of CBD with that result, and it measured opioid use, not pain scores. Its authors concluded that the opioid-sparing effect of cannabinoids “remains uncertain based on current evidence”. In the emergency back-pain trial, oxycodone use was similar on CBD and placebo. In a 2026 pilot trial of 36 adults having both knees replaced, the planned test found no significant difference from placebo in opioid use over 72 hours (400 mg doses: 144 vs 209 MME, p=0.10; 800 mg doses: 203.2 vs 209 MME, p=0.98; MME means morphine milligram equivalents). A post hoc test favored 400 mg doses (p=0.04), and the 400 mg group also had lower pain scores and needed fewer rescue pain medicines, but used more anti-inflammatory pain medicines (NSAIDs); the 800 mg group showed no opioid-sparing effect and had more side effects, and anxiety and depression scores were higher on CBD, particularly at 800 mg, though the trial’s registry results show those scores were already higher in the CBD groups before surgery. The abstract gives no figures or test results for these secondary results. In a 2021 pilot trial of 30 adults with stage IV cancer, more of those who started medical cannabis with THC and CBD early, rather than after a 3-month delay, reduced their opioid use and had better pain control (no placebo group; no figures in the abstract).

Before changing any prescribed medicine, see the safety section below.

CBD side effects, drug interactions and who should avoid CBD

Talk to your doctor before using CBD, especially if you take any medicines or supplements, have liver problems, or have a health condition.

Side effects reported in CBD trials

In placebo-controlled trials of prescription CBD for seizure disorders, at 10 or 20 mg/kg a day (doses above most of those in the pain trials in this article), sleepiness or sedation affected 32% vs 11% on placebo. Decreased appetite, diarrhea, liver-enzyme rises, tiredness, rash, insomnia and infections were also common. The FDA also lists irritability and agitation. A 2026 review of 3 trials in chemotherapy nerve pain, testing CBD taken by mouth, CBD on the skin and nabiximols, found fatigue, dizziness and dry mouth were the most common side effects. The FDA has warned of possible harm to the male reproductive system, seen in animal studies; a 2025 FDA trial found no hormone changes over 4 weeks.

CBD and your liver

In a 2025 FDA-run trial of 201 healthy adults, 5.6% of those taking 5 mg/kg of CBD a day had liver-enzyme rises above 3 times normal within 4 weeks, versus none on placebo. A 2023 meta-analysis found rises in about 7% of trial participants. High doses (1,000 mg a day or 20 mg/kg a day and above) and use with seizure medicines raised the risk, and no cases were reported in adults taking under 300 mg a day.

Drug interactions

CBD can affect how other medicines work, which can cause serious side effects. Using CBD with alcohol or with medicines that cause drowsiness, such as some medicines for anxiety, panic, stress or sleep, raises the risk of sleepiness and injury.

CYP450 enzymes are liver enzymes that break down many medicines.

Medicine or group What is known Source
Blood thinners such as warfarin INR (a blood-clotting test) rose in 6 of 7 case reports of cannabis or CBD use, at very high or unknown doses; very low-quality evidence [44]
Medicines processed by CYP2C19 and CYP3A4 CBD is broken down by them and slows CYP2C19; levels of clobazam’s active form and of everolimus rose [39]
Alcohol and sedating medicines More sleepiness [40]
Acetaminophen, opioid painkillers and antidepressants Possible interactions listed in a review; more liver-enzyme rises with CBD added to acetaminophen in one trial (15 vs 5 people) [37] [16]
Amitriptyline and tramadol (pain medicines) In 12 healthy volunteers, a single 30 mg dose of CBD raised amitriptyline blood exposure over 24 hours by 13% and its peak level by 17%; tramadol levels did not change significantly. The authors say interactions may be more pronounced with daily use [57]
Opioids and other medicines in advanced cancer In a 2026 analysis of the advanced-cancer trial in the study table (144 people), CBD did not raise the likelihood of a new or worse side effect, overall or with specific medicines, and the CBD dose people chose was not related to opioid use; the analysis used chosen doses and reported side effects, not blood levels [58]

Do not stop, reduce or change any prescribed medicine or treatment without talking to the doctor who prescribed it.

Who should avoid CBD

Do not use CBD if you are pregnant, planning a pregnancy or breastfeeding. The FDA strongly advises against using CBD, THC or marijuana in any form during pregnancy or while breastfeeding.

CBD products are not for children. Keep them out of reach of children and pets. If a child swallows a CBD or THC product, call Poison Control at 1-800-222-1222 or get medical care right away.

When to see a doctor about pain

Get emergency care (call 911) for sudden, severe or unexplained pain, chest pain, trouble breathing, or signs of a stroke.

New, worsening or long-lasting pain needs a doctor’s diagnosis. Bring a list of your medicines and supplements, ask about CBD interactions and liver tests, and keep a pain diary.

What should you look for in a CBD product?

How to check a CBD product’s quality: read its certificate of analysis (COA) from an accredited third-party lab. See our guides to reading a COA and verifying the lab. Look for a COA matching the batch number that lists CBD per serving, total THC and contaminants. For THC limits, see Is CBD legal?

Labels are not always accurate: a 2024 study that tested 202 CBD products sold in the US found that 74% missed their labeled CBD amount by 10% or more. Contaminants were common but mostly within limits: heavy metals turned up in 44 of the 202 products, residual solvents in 181 and pesticides in 30, and only 1% to 3% of detections exceeded a regulatory limit. Jazz Pharmaceuticals, the maker of Epidiolex, funded and co-designed the study.

The FDA says CBD cannot be sold as a dietary supplement or added to food in interstate commerce; in 2023 it called for a new regulatory pathway.

Hemp seed oil vs CBD oil: read the label

“Hemp oil” on a label can mean hemp seed oil, which is pressed from seeds and contains only trace amounts of CBD, or a CBD extract; the COA shows which. A CBD oil is CBD extract in a carrier oil, such as MCT oil (used in a 2026 study) or hemp seed oil.

Hemp and marijuana are both forms of the Cannabis sativa plant. How federal law defines hemp, and how that definition changes on November 12 and December 11, 2026, is explained under “Is CBD legal?”.

Full-spectrum, broad-spectrum or isolate?

Full-spectrum products contain other cannabinoids and some THC; broad-spectrum products keep other cannabinoids with the THC removed; isolate is CBD only. In the 2024 test, 26% of products were not the type their label claimed. See full-spectrum vs broad-spectrum vs pure CBD.

Is CBD legal? Federal law is changing. Under the 2018 Farm Bill definition, hemp (including hemp-derived CBD) is cannabis with no more than 0.3% delta-9 THC by dry weight, and it is not a controlled substance. A new federal definition applies in two steps (section 781 of Public Law 119-37, with start dates set by Public Law 119-103). Starting November 12, 2026, hemp products that contain cannabinoids the plant cannot produce naturally no longer count as hemp. Starting December 11, 2026, the rest of the definition applies. It counts total THC, including THCA, and a finished hemp product such as a CBD oil or gummy qualifies as hemp only if each container holds no more than 0.4 mg of total THC and similar cannabinoids, and contains no cannabinoids that were synthesized or manufactured outside the plant. Some full-spectrum CBD products contain more THC than that. State laws differ and can be stricter. This is general information, not legal advice.

Frequently asked questions

What does research show about CBD as a painkiller?

Results are mixed. Of 44 randomized trials of CBD alone or CBD-dominant products in our review, 7 found lower pain, 5 had mixed or early results, 29 found no advantage over placebo and 3 could not be judged. A 2024 Journal of Pain review found a benefit in 1 of 16 trials, and in the largest trial since (200 adults with fibromyalgia) pain fell more on placebo. Trials that found lower pain include one in severe toothache and one in nerve pain after spinal cord injury.

What forms of CBD have pain studies tested?

Most trials gave CBD by mouth as oils, tablets or capsules. Some found lower pain, such as single doses for toothache and high daily doses for nerve pain after spinal cord injury, and most found no difference from placebo. Of 8 small trials of CBD on the skin, 3 found lower pain, 4 no difference and 1 mixed results; a 2023 review rated the earlier ones at high risk of bias. We found no gummy trial.

What are the potential side effects of long-term CBD use?

In 2023 the FDA said it had not found adequate evidence on how much CBD can be consumed, and for how long, before causing harm. The longest trial in our study table ran 24 weeks. A 2023 meta-analysis found that high doses and use with seizure medicines raised the risk of liver-enzyme rises, and no cases were reported in adults taking under 300 mg a day (see CBD and your liver).

What are the potential side effects of taking CBD gummies?

Gummies may cause the side effects seen with CBD taken by mouth in trials, such as sleepiness, diarrhea, decreased appetite and liver-enzyme changes, especially at higher doses (FDA). Labels may not match the contents: a 2025 test of 56 CBD gummy products found many that were off their labeled CBD amount or contained THC (details under Do CBD gummies work for pain?). For children and pets, see Who should avoid CBD.

How long does CBD take to work?

A 2018 review of 24 studies found that CBD reached its peak blood level within 0-4 hours, fastest when inhaled and higher with food or oil-based formulas. In a 2024 meta-analysis, eating just before or with CBD raised the amount of CBD in the blood about 2 to 5 times. In the toothache trial, pain fell more than with placebo over the 3 hours after one large dose, most at 3 hours, when observation ended.

Will CBD show up on a drug test?

Some CBD products contain THC, even when the label says they don’t. Using CBD can lead to a positive drug test. In a 2026 controlled study, at least one person in every group taking CBD oil with a little THC tested positive, as did one urine sample from the CBD-only group. One author worked for a CBD company.

In a 2026 systematic review, 5 of 8 studies that tested people after CBD or hemp oil use reported that the oils would not produce a result above a drug test’s THC cut-off, though trace or near-limit levels were found. The review tied positive tests to what is in the product (such as undeclared THC or mislabeling), the sample tested, how the product is taken and how sensitive the test is.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have about a medical condition.

These statements have not been evaluated by the Food and Drug Administration. Hemp-derived CBD products are not intended to diagnose, treat, cure, or prevent any disease.

For side effects, drug interactions, pregnancy and breastfeeding, and who should avoid CBD, see the safety section above.

For federal and state law, see Is CBD legal?

How we researched this

We do not sell or recommend products on this page. Every study cited was checked at PubMed or the publisher. Figures from Cannabidiol Life’s Evidence Tracker show the date and source used. Registry, PubMed-count and search figures are as of October 23, 2026; trial tables and tallies are as of November 13, 2026. That day we searched Cannabidiol Life’s research library (5,059 PubMed records), found 1,091 papers on CBD or medical cannabis and pain that were not yet in our review, checked 160 of them at PubMed and added 14 studies that met this page’s rules. On the same day we also added 15 more sources from our October research: 10 reviews and meta-analyses of human studies, 2 clinical guidelines, 2 expert consensus or position papers and 1 meta-analysis of animal studies. Each reported a benefit or a favorable signal for cannabis-based medicines or cannabinoids, or advised that they may be considered. They are a selection, not a full list of reviews. None of them is a review of CBD alone; where a review’s summary gives a separate CBD result, the text gives it too.

Every human trial in our review

This table lists every human randomized trial in our verified evidence review, as of November 13, 2026: the 44 trials of CBD alone or CBD-dominant products counted in the tally above, 7 laboratory pain studies, 14 papers on 15 trials of CBD with THC and 2 THC-dominant trials. Amounts are left out here; the study table above gives them for the trials this article discusses. Each study name links to its PubMed or ClinicalTrials.gov record.

Study and year People Product Pain type Main result
CBD alone or CBD-dominant (44 trials)
Zhou 2026 35 CBD (low-THC), by mouth After eye surgery No difference from codeine plus acetaminophen; no placebo
Robertson 2026 40 CBD, by mouth Nerve pain after spinal cord injury Pain 0.54 points lower than placebo (0-10 scale); more mild side effects
Reeve 2026 54 CBD oil (THC not stated) Jaw muscle pain (TMD) No difference
Anelli 2026 102 CBD-enriched oil Endometriosis pelvic pain No difference; stopped early; more mild digestive side effects
Stauffer 2026 29 CBD-rich hemp extract, under the tongue Induced muscle injury, healthy adults Less peak pain at 48 hours; early estimates
Mendes 2026 15 CBD on the skin Muscle soreness after jumping exercise No difference in soreness
Rasmussen 2026 200 CBD tablets Fibromyalgia Pain fell more on placebo
Schuster 2026 92 Inhaled flower: CBD-dominant, THC-dominant, or THC with CBD Migraine CBD-dominant flower no better than placebo; more attacks pain-free with THC plus CBD (34.5% vs 15.5%)
Kubota 2026 101 CBD-dominant oil Parkinson’s disease pain No difference
McMaster University (registry results) 39 CBD-dominant, by mouth, with a little THC Knee replacement surgery No advantage on registry outcomes; no journal paper found
Sideris 2026 (registry record) 36 CBD by mouth Replacement of both knees Planned test: no significant difference from placebo in opioid use over 72 hours; post hoc test favored 400 mg doses, and that group also had lower pain scores; 800 mg group: no opioid-sparing effect, more side effects
Mojoli 2025 45 CBD-rich full-spectrum oil Knee osteoarthritis No difference
Abidi 2025 8 CBD by mouth After tooth extraction Descriptive only (2 people per group)
Murina 2025 40 CBD gel with myrcene Vulvar pain (vestibulodynia) Pain not different; only pain during sex improved more
Pastina 2025 28 CBD cream Muscle fatigue after exercise No difference
Haney 2025 12 CBD-dominant capsules with some THC Chemotherapy nerve pain (breast cancer) Worse than placebo on neuropathy, sleep and pain interference
Montefiore Medical Center (registry results) 35 High-CBD capsules, plus THC groups HIV with chronic pain No advantage for the high-CBD group
Weiss 2025 46 CBD-dominant hemp extract with some THC Chemotherapy nerve pain No difference
Sahinovic 2025 25 CBD by mouth, single dose (2 dose levels) Pain during a treadmill run, trained runners No difference at either dose (secondary rating)
de Andrade Silva 2024 Not stated CBD-rich extract After root canal treatment No difference
D’Andre 2024 40 CBD isolate on the skin Chemotherapy nerve damage No difference
Walczyńska-Dragon 2024 60 CBD applied in the mouth Jaw muscle pain with tooth grinding Pain fell 41% to 57%; no significant change on placebo
Chrepa 2024 61 CBD, single oral dose Severe toothache Pain lower than placebo over 3 hours; more sedation and diarrhea
McCartney 2024 52 CBD capsules, single dose Pain during a 10 km run, healthy adults No difference (secondary rating)
Pramhas 2023 86 CBD by mouth, with paracetamol Knee osteoarthritis No difference; more liver-enzyme rises
Narang 2023 90 CBD by mouth After a kidney-stone procedure No difference in pain or opioid use
Hardy 2023 144 CBD oil Advanced cancer, palliative care No difference in symptoms, including pain
Zubcevic 2023 118 CBD capsules, plus THC groups Nerve pain No benefit; CBD group about 1 point worse
Hansen 2023 134 CBD, plus THC groups Nerve pain with MS or spinal cord injury No difference
Umpreecha 2023 69 CBD on mouth ulcers Mouth ulcers Pain lower than placebo on 1 day only
Stone 2023 4 CBD oil Soreness after arm exercise No difference (very small study)
Vela 2022 136 CBD by mouth Hand osteoarthritis or psoriatic arthritis No difference
Alaia 2022 99 CBD tablet held in the cheek Shoulder (rotator cuff) surgery Lower pain on day 1 only; no difference at 1 year
Heineman 2022 18 CBD cream Thumb arthritis Lower pain than the control cream
Haffar 2022 80 CBD on the skin Knee replacement surgery No difference in pain or opioid use
van Orten-Luiten 2022 32 CBD chewing gum Irritable bowel syndrome No difference
Atieh 2022 Not stated CBD by mouth Upper belly pain (functional dyspepsia) No difference in symptoms
Bebee 2021 100 CBD, single oral dose Sudden low back pain, emergency room No difference at 2 hours
Cochrane-Snyman 2021 13 CBD oil Muscle soreness after exercise No difference
Xu 2020 29 CBD on the skin Nerve damage in the legs Less intense and sharp pain than placebo
Nitecka-Buchta 2019 60 CBD on the skin Jaw muscle pain (TMD) Pain fell 70% vs 10% on placebo
van de Donk 2019 20 Inhaled CBD-dominant cannabis, plus THC varieties Fibromyalgia CBD-dominant variety no better than placebo
Notcutt 2004 34 CBD extract under the tongue, plus THC extracts Chronic, mainly nerve pain No separate CBD result reported; THC extracts did best
Wade 2003 24 CBD extract under the tongue, plus THC extracts Nerve-related symptoms, mostly MS Pain scores better than placebo with both CBD and THC extracts
Laboratory pain studies (7)
Costa 2026 23 CBD Lab pain tests, people on methadone Mixed: better pain inhibition before methadone, lower heat-pain threshold after
Bergeria 2025 31 CBD with an opioid Lab pain tests, healthy adults Mixed: added effect on some short-term lab measures; more bad effects
Gorbenko 2024 37 CBD added to THC Lab pain tests, healthy adults No added pain effect; stronger THC high
Dieterle 2022 24 CBD Lab pain model, healthy adults No difference
Schneider 2022 20 CBD Electrical lab pain, healthy adults No difference
Arout 2022 17 CBD Lab pain tests, healthy adults No consistent effect; painfulness ratings higher than placebo
De Vita 2022 15 CBD Lab pain tests, healthy adults No effect on pain threshold; being told it was CBD changed some responses
CBD with THC (14 papers, 15 trials)
Kurlyandchik 2026 24 1:1 THC:CBD oil Fibromyalgia 70% vs 20-40% on placebo had at least 30% less pain (pilot)
Kruger 2026 164 3 cannabinoid products, one with THC; no placebo Fibromyalgia, rheumatoid arthritis or osteoarthritis Symptoms improved on all products; no placebo group
Hardy 2025 144 1:1 THC:CBD Advanced cancer, palliative care No difference in overall symptoms; pain improved slightly more, with more mind-altering side effects
Zylla 2021 30 Medical cannabis with THC and CBD; no placebo Stage IV cancer, on opioids More people cut opioid use and had better pain control with early cannabis than with a delayed start (pilot; no figures in abstract)
Abrams 2020 27 Vaporized cannabis with THC and CBD Sickle cell disease No difference in pain
Lichtman 2018 397 Nabiximols spray Cancer pain despite opioids Main goal not met
Fallon 2017 Not stated (2 trials) Nabiximols spray Cancer pain despite opioids Main goal not met in either trial
Serpell 2014 246 Nabiximols spray Nerve pain with touch sensitivity More responders on nabiximols; average pain not different
Langford 2013 339 Nabiximols spray MS nerve pain Main goal not met
Portenoy 2012 360 Nabiximols spray Cancer pain despite opioids Main goal not met
Johnson 2010 177 THC:CBD extract, plus a THC extract Cancer pain despite opioids Pain fell more on THC:CBD than placebo (1.37 vs 0.69 points); THC alone not different
Nurmikko 2007 125 Nabiximols spray Nerve pain with touch sensitivity Pain fell 1.48 vs 0.52 points
Rog 2005 66 Nabiximols spray MS central pain Pain fell 2.7 vs 1.4 points
Berman 2004 48 Nabiximols-type and THC extracts Nerve pain after brachial plexus injury Smaller change than expected; some pain gains significant
THC-dominant, for reference (2 trials)
Karst 2025 820 THC extract with almost no CBD Chronic low back pain Pain 0.6 points lower; more side effects
Seevathee 2025 100 THC-dominant oil with some CBD and CBN, on the skin Diabetic nerve pain in the legs and feet Nerve-pain score fell from 25.60 to 5.57 vs 25.24 to 22.85 on placebo

Verified at PubMed or ClinicalTrials.gov as of November 13, 2026.

Sources

The 77 sources cited in the article. Sources 1 to 47 are in order of first citation; sources 48 to 62 were added on November 13, 2026. Sources 63 to 77, added the same day, are the reviews, guidelines and expert papers from our October research, in order of first citation. Trials listed only in the appendix are linked in that table.

  1. Moore A, Straube S, Fisher E, et al. Cannabidiol (CBD) Products for Pain: Ineffective, Expensive, and With Potential Harms. J Pain. 2024;25(4):833-842. PubMed 37863344
  2. Chou R, Fu R, Ahmed AY, et al. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review. Ann Intern Med. 2026;179(2):230-241. PubMed 41429020
  3. US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers (content current as of 07/16/2024). fda.gov. 2024. fda.gov
  4. Rasmussen MU, Christensen R, Wæhrens EE, et al. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Ann Rheum Dis. 2026;85(3):566-574. PubMed 40846590
  5. Lo LA, Christiansen A, Eadie L, et al. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PubMed 36912195
  6. Ateş G, Welsch P, Klose P, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2026;1(1):CD012182. PubMed 41548880
  7. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Chapter 4, Therapeutic Effects (Conclusion 4-1). National Academies Press. 2017. PubMed 28182367
  8. Mohammed SYM, Leis K, Mercado RE, et al. Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain Manag Nurs. 2024;25(2):e76-e86. PubMed 37953193
  9. Hardy J, Greer R, Huggett G, et al. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol. 2023;41(7):1444-1452. PubMed 36409969
  10. Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. PubMed 34510141
  11. Hansen JS, Gustavsen S, Roshanisefat H, et al. Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. Pharmaceuticals (Basel). 2023;16(8). PubMed 37630995
  12. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain. 2023;27(4):492-506. PubMed 36571471
  13. Anelli GB, Ratochinski R, Oliveira IGC, et al. Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. Cannabis Cannabinoid Res. 2026. doi:10.1177/25785125251413989. PubMed 42261989
  14. Kubota GT, Parmera JB, Deltreggia M, et al. Cannabis-Based Oil for Pain and Other Non-Motor Symptoms in Parkinson’s Disease: A Randomized Controlled Trial. Mov Disord. 2026. PubMed 42563548
  15. Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust. 2021;214(8):370-375. PubMed 33846971
  16. Pramhas S, Thalhammer T, Terner S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Lancet Reg Health Eur. 2023;35:100777. PubMed 38033459
  17. Zhou Y, Swiatek K, Nguyen A, et al. Randomized, controlled crossover comparison of oral cannabidiol with oral opioid for postoperative PRK pain control. J Cataract Refract Surg. 2026. PubMed 42524865
  18. Robertson RV, Suraev A, McCartney D, et al. High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. EClinicalMedicine. 2026;96:103986. PubMed 42256679
  19. Chrepa V, Villasenor S, Mauney A, et al. Cannabidiol as an Alternative Analgesic for Acute Dental Pain. J Dent Res. 2024;103(3):235-242. PubMed 37910667
  20. Heineman JT, Forster GL, Stephens KL, et al. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022;47(7):611-620. PubMed 35637038
  21. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984-97. PubMed 23180178
  22. Karst M, Meissner W, Sator S, et al. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nat Med. 2025;31(12):4189-4196. PubMed 41023483
  23. Cochrane-Snyman KC, Cruz C, Morales J, et al. The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Med Sci Sports Exerc. 2021;53(7):1460-1472. PubMed 33481484
  24. Stauffer JW, Crow JA, Bishop MD, et al. Efficacy and safety of cannabidiol (CBD) on reducing pain and functional impairment associated with exercise-induced muscle injury: a randomized placebo-controlled feasibility trial. J Cannabis Res. 2026;8(1). PubMed 41918004
  25. Schuster NM, Wallace MS, Marcotte TD, et al. Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. Headache. 2026;66(2):365-376. PubMed 41469488
  26. Villanueva MRB, Joshaghani N, Villa N, et al. Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review. Cureus. 2022;14(7):e26913. PubMed 35860716
  27. Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci. 2020;21(22). PubMed 33238607
  28. Millar SA, Stone NL, Yates AS, et al. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. PubMed 30534073
  29. Xu DH, Cullen BD, Tang M, et al. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2020;21(5):390-402. PubMed 31793418
  30. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019;8(11). PubMed 31698733
  31. van de Donk T, Niesters M, Kowal MA, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860-869. PubMed 30585986
  32. Johnson ED, Kilgore MW, Stafford M, et al. Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res. 2025;10(6):710-718. PubMed 40454463
  33. Scholfield CN, Waranuch N, Kongkaew C. Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. Cannabis Cannabinoid Res. 2023;8(4):589-602. PubMed 35605018
  34. Spindle TR, Sholler DJ, Cone EJ, et al. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. JAMA Netw Open. 2022;5(7):e2223019. PubMed 35857320
  35. Boehnke KF, Gagnier JJ, Matallana L, et al. Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia. J Pain. 2022;23(1):45-54. PubMed 34214700
  36. Abidi AH, Kassan M, Derefinko K. Oral Cannabidiol for Acute Post-Extraction Pain: A Randomized Pilot Study. Pharmaceuticals (Basel). 2025;18(12). PubMed 41471281
  37. Balachandran P, Elsohly M, Hill KP. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. J Gen Intern Med. 2021;36(7):2074-2084. PubMed 33515191
  38. Noori A, Miroshnychenko A, Shergill Y, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7):e047717. PubMed 34321302
  39. Jazz Pharmaceuticals, Inc. EPIDIOLEX (cannabidiol) oral solution: Full Prescribing Information (revised 5/2026; Medication Guide revised 7/2025). DailyMed (US National Library of Medicine), SPL version 35, published June 15, 2026. dailymed.nlm.nih.gov
  40. US Food and Drug Administration. What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD (consumer update; content current as of 03/05/2020). fda.gov. 2020. fda.gov
  41. Datta A, Erridge S, Mukherjee A, et al. Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials. J Pain Palliat Care Pharmacother. 2026;40(3):458-473. PubMed 42085369
  42. US Food and Drug Administration (statement by Janet Woodcock, MD). FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward (January 26, 2023). FDA press announcement. 2023. fda.gov
  43. Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(9):1070-1078. PubMed 40622698
  44. Smythe MA, Wu W, Garwood CL. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy. 2023;43(12):1327-1338. PubMed 37740600
  45. US Food and Drug Administration. What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding (consumer update; content current as of 10/16/2019). fda.gov. 2019. fda.gov
  46. Gidal BE, Vandrey R, Wallin C, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol. 2024;15:1335441. PubMed 38562466
  47. Wolinsky D, Zamarripa CA, Spindle TR, et al. The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol. J Anal Toxicol. 2026;50(1). PubMed 40704705
  48. Till SR, Whitmore G, As-Sanie S, et al. Cannabidiol Use and Perceptions of Effectiveness in Women With Chronic Pelvic Pain. J Obstet Gynaecol Can. 2025;47(7):102839. PubMed 40216330
  49. Erridge S, Datta A, Mukherjee A, et al. Pain Severity Trajectories and Patient Profiles in Chronic Pain Patients Treated with Cannabis-Based Medicinal Products: A k-Means Clustering Analysis of the UK Medical Cannabis Registry. J Clin Pharmacol. 2026;66(10):e70313. PubMed 42885647
  50. Sideris A, Chan W, Liu J, et al. Effects of cannabidiol (CBD) oral solution in patients undergoing bilateral total knee arthroplasty: A randomized, controlled, parallel, triple blind, pilot study. J Pain. 2026;51:106477. PubMed 42913966
  51. McCartney D, Irwin C, Bawa Z, et al. The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial. Sports Med Open. 2024;10(1):61. PubMed 38782848
  52. Sahinovic A, Lau NS, Sabag A, et al. The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial. Sports Med Open. 2025;11(1):96. PubMed 40839290
  53. Almuntashiri N, El Sharazly BM, Carter WG. Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review. Biomolecules. 2025;15(6). PubMed 40563456
  54. Salz T, Mishra Meza A, Chino F, et al. Cannabidiol and Cancer Survivors: Utilization and Experiences. J Palliat Med. 2026;29(8):1096-1105. PubMed 42198914
  55. Lisano JK, Rosa L, Skrzynski CJ, et al. Lower Pain Intensity Is Associated with the Use of Recreational Edible Cannabis Products Containing Delta-9-Tetrahydrocannabinol: A Secondary Analysis in Adults Self-Managing Their Chronic Low Back Pain. Biomedicines. 2026;14(7). PubMed 42512114
  56. Zylla DM, Eklund J, Gilmore G, et al. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. 2021;29(12):7471-7478. PubMed 34085149
  57. Gorbenko AA, Post TE, Strugala PK, et al. Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study. Br J Clin Pharmacol. 2026;92(6):1595-1606. PubMed 41398552
  58. Downs G, Greer R, Moses G, et al. Drug Interactions in People on Cannabidiol: Is There Cause for Concern? Cannabis Cannabinoid Res. 2026;11(2):138-146. PubMed 39539239
  59. Jang JH, Jeong JH, Jeong SH. Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(11):8285-8309. PubMed 38850302
  60. Ovat DY, Bezci E, Balıca K, et al. Impact of CBD and hemp oil use on drug test results: a systematic review. Int J Legal Med. 2026;140(4):2065-2078. PubMed 41942676
  61. Seevathee K, Kessomboon P, Manimmanakorn N, et al. Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities. Med Cannabis Cannabinoids. 2025;8(1):1-14. PubMed 39720705
  62. Melendez SN, Ortiz Torres M, Lisano JK, et al. Edible cannabis for chronic low back pain: associations with pain, mood, and intoxication. Front Pharmacol. 2024;15:1464005. PubMed 39380911
  63. Jeddi HM, Busse JW, Sadeghirad B, et al. Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open. 2024;14(1):e068182. PubMed 38171632
  64. Bell AD, MacCallum C, Margolese S, et al. Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis Cannabinoid Res. 2024;9(2):669-687. PubMed 36971587
  65. Solmi M, De Toffol M, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348. PubMed 37648266
  66. Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259. PubMed 35982439
  67. Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021;374:n2040. PubMed 34497062
  68. Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. PubMed 34497047
  69. Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):22. PubMed 34215346
  70. Fisher E, Moore RA, Fogarty AE, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66. PubMed 32804836
  71. Lam PM, Wang F, Shing CH, et al. Analgesic Effect of Cannabinoids for Fibromyalgia: A Systematic Review and Meta-Analysis. Pain Physician. 2026;29(2):95-107. PubMed 42013320
  72. Sherman JJ, Riche DM. Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review. Cannabis Cannabinoid Res. 2026;11(2):114-124. PubMed 41714301
  73. Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547-1564. PubMed 30074291
  74. Costa-Oliveira CD, Castro MJ, Silvério LAL, et al. Efficacy and Safety of Cannabinoid-Based Interventions for Low Back Pain and Migraine: A Systematic Review of Randomized Controlled Trials. Cannabis Cannabinoid Res. 2026. doi:10.1177/25785125261490003. PubMed 42773786
  75. Lee C, Danielson EC, Beestrum M, et al. Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review. Curr Pain Headache Rep. 2023;27(12):821-835. PubMed 38041708
  76. Soliman N, Haroutounian S, Hohmann AG, et al. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-S44. PubMed 33729209
  77. El-Mourad J, Lunghi C, Herrera NP, et al. Dosing of Cannabinoids Associated with an Opioid-Sparing Effect: A Systematic Review of Longitudinal Studies. Pain Manag Nurs. 2024;25(1):e8-e20. PubMed 37689509

CBD and health research · CBD for sleep · CBD for anxiety · CBD for arthritis · CBD for inflammation · How to read a certificate of analysis (COA) · How to verify the lab on a COA

DON'T BE SHY

Leave a Reply

Your email address will not be published. Required fields are marked *

Pattern of white dots.
Cannabidiol Life white menu logo

IMPORTANT DISCLAIMER: